Equity

Vertex Pharmaceuticals·Balance Sheet Statement·10 metrics

Breakdown

Metric	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Total liabilities and stockholders' equity	$20.1B	$22.2B	$22.5B	$22.9B	$24.0B	$24.9B	$25.6B	$26.5B
Total stockholders' equity	$14.8B	$15.6B	$16.4B	$16.5B	$17.2B	$17.3B	$18.7B	$19.4B
Retained earnings	$7.6B	$8.7B	$9.6B	$10.3B	$11.3B	$12.4B	$13.6B	$14.6B
Additional paid-in capital	$7.1B	$6.9B	$6.7B	$6.2B	$6.0B	$5.0B	$5.1B	$4.7B
Investments - Gross Unrealized Losses	$4.6B	$443.8M	—	$1.1B	$816.0M	$463.1M	—	$3.4B
Share Repurchase Program - Amount Remaining	$2.1B	$1.8B	—	$964.4M	$4.6B	$3.5B	—	$3.0B
Accumulated other comprehensive income (loss)	$22.5M	$28.8M	$127.8M	$68.1M	-$101.1M	-$64.5M	-$15.9M	$24.8M
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	$382.4M	$68.6M	—	$7.6M	$6.2M	$9.9M	—	$8.4M
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$2.6M	$2.6M	$2.6M	$2.6M	$2.6M	$2.5M	$2.5M	$2.5M
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0	$0.0